<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>WHO 2026 GLP-1 Compliance Pack ‚Äì Clinics, Telehealth & Pharmacies</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="description"
        content="WHO 2026 GLP-1 Global Risk Advisory ‚Äì compliance actions for clinics, telehealth providers, pharmacies, compounders and distributors: documentation, cold-chain, marketing, audits." />
  <meta name="robots" content="index,follow" />
  <meta name="date" content="2026-01-01" />
  <meta name="last-modified" content="2026-01-01" />
  <link rel="icon" href="/favicon.ico" />
  <link rel="canonical" href="https://skillona.ai/glp1-who-guidance-2026/" />

  <!-- Open Graph -->
  <meta property="og:title" content="WHO 2026 GLP-1 Compliance Pack ‚Äì Clinics & Telehealth" />
  <meta property="og:description"
        content="GLP-1 WHO 2026 Global Risk Advisory: required documentation, off-label rules, cold-chain, compounding and marketing compliance for clinics, telehealth, pharmacies and compounders." />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://skillona.ai/glp1-who-guidance-2026/" />
  <meta property="og:image" content="https://skillona.ai/assets/og/glp1-who-guidance-2026.png" />
  <meta property="article:published_time" content="2026-01-01" />
  <meta property="article:modified_time" content="2026-01-01" />

  <!-- Twitter -->
  <meta name="twitter:card" content="summary_large_image" />
  <meta name="twitter:title" content="WHO 2026 GLP-1 Compliance Pack ‚Äì Providers" />
  <meta name="twitter:description"
        content="WHO GLP-1 Global Risk Advisory 2026: one compliance pack for clinics, telehealth platforms, pharmacies and compounders." />
  <meta name="twitter:image" content="https://skillona.ai/assets/og/glp1-who-guidance-2026.png" />

  <!-- STYLE (ChexSystems blue template) -->
  <style>
    :root {
      --bg: #050814;
      --bg-elevated: #0b1220;
      --bg-soft: #101827;
      --accent: #38bdf8;
      --accent-soft: rgba(56, 189, 248, 0.12);
      --text: #e5e7eb;
      --muted: #9ca3af;
      --border-subtle: #1f2937;
      --danger: #f97373;
      --success: #4ade80;
      --radius-lg: 18px;
      --radius-xl: 26px;
      --shadow-soft: 0 18px 45px rgba(0, 0, 0, 0.55);
      --max-width: 900px;
    }

    * {
      box-sizing: border-box;
      -webkit-font-smoothing: antialiased;
      text-rendering: optimizeLegibility;
    }

    body {
      margin: 0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "SF Pro Text",
        "Segoe UI", sans-serif;
      background: radial-gradient(circle at top, #111827 0, #020617 55%, #000 100%);
      color: var(--text);
      min-height: 100vh;
      display: flex;
      justify-content: center;
    }

    .page {
      width: 100%;
      max-width: var(--max-width);
      padding: 28px 18px 40px;
    }

    @media (min-width: 768px) {
      .page {
        padding: 40px 0 64px;
      }
    }

    .shell {
      background: linear-gradient(145deg, rgba(15, 23, 42, 0.96), rgba(2, 6, 23, 0.98));
      border-radius: 32px;
      padding: 28px 20px 30px;
      box-shadow: var(--shadow-soft);
      border: 1px solid rgba(148, 163, 184, 0.16);
      backdrop-filter: blur(26px);
    }

    @media (min-width: 768px) {
      .shell {
        padding: 32px 36px 38px;
      }
    }

    header {
      display: flex;
      flex-direction: column;
      gap: 12px;
      margin-bottom: 26px;
    }

    .tagline {
      font-size: 13px;
      letter-spacing: 0.16em;
      text-transform: uppercase;
      color: var(--muted);
      display: flex;
      align-items: center;
      gap: 10px;
      flex-wrap: wrap;
    }

    .tagline-pill {
      padding: 4px 10px;
      border-radius: 999px;
      background: rgba(15, 23, 42, 0.9);
      border: 1px solid var(--border-subtle);
      display: inline-flex;
      align-items: center;
      gap: 6px;
    }

    .tag-dot {
      width: 6px;
      height: 6px;
      border-radius: 999px;
      background: var(--accent);
      box-shadow: 0 0 0 4px var(--accent-soft);
    }

    h1 {
      font-size: 26px;
      line-height: 1.15;
      letter-spacing: -0.03em;
      margin: 0;
    }

    @media (min-width: 768px) {
      h1 {
        font-size: 32px;
      }
    }

    .subtitle {
      color: var(--muted);
      font-size: 15px;
      max-width: 640px;
    }

    .meta-row {
      display: flex;
      flex-wrap: wrap;
      gap: 10px;
      margin-top: 6px;
      font-size: 12px;
      color: var(--muted);
    }

    .meta-pill {
      padding: 4px 9px;
      border-radius: 999px;
      border: 1px solid var(--border-subtle);
      background: rgba(15, 23, 42, 0.85);
      display: inline-flex;
      align-items: center;
      gap: 6px;
    }

    .meta-pill strong {
      font-weight: 600;
      color: #e5e7eb;
    }

    main {
      display: grid;
      grid-template-columns: minmax(0, 1.9fr) minmax(0, 1.1fr);
      gap: 18px;
    }

    @media (max-width: 900px) {
      main {
        grid-template-columns: minmax(0, 1fr);
      }
    }

    .article {
      background: radial-gradient(circle at top left, rgba(56, 189, 248, 0.12), transparent 55%),
                  radial-gradient(circle at bottom right, rgba(129, 140, 248, 0.12), transparent 52%),
                  linear-gradient(145deg, #020617, #020617);
      border-radius: var(--radius-xl);
      border: 1px solid rgba(55, 65, 81, 0.9);
      padding: 20px 18px 22px;
      position: relative;
      overflow: hidden;
    }

    @media (min-width: 768px) {
      .article {
        padding: 22px 22px 24px;
      }
    }

    .article::before {
      content: "";
      position: absolute;
      inset: 0;
      background: radial-gradient(circle at top right, rgba(59, 130, 246, 0.18), transparent 60%);
      opacity: 0.7;
      pointer-events: none;
      mix-blend-mode: soft-light;
    }

    .article-inner {
      position: relative;
      z-index: 1;
    }

    .section-label {
      font-size: 11px;
      letter-spacing: 0.16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 6px;
    }

    .article h2 {
      font-size: 18px;
      margin-top: 20px;
      margin-bottom: 8px;
      letter-spacing: -0.02em;
    }

    .article h3 {
      font-size: 15px;
      margin-top: 16px;
      margin-bottom: 6px;
    }

    .article p {
      font-size: 14px;
      line-height: 1.6;
      color: #d1d5db;
      margin: 6px 0 8px;
    }

    .article ul,
    .article ol {
      margin: 6px 0 10px 0;
      padding-left: 18px;
      font-size: 14px;
      color: #d1d5db;
    }

    .article li {
      margin-bottom: 5px;
    }

    .callout {
      margin: 14px 0 12px;
      padding: 10px 12px;
      border-radius: 14px;
      background: rgba(15, 23, 42, 0.96);
      border: 1px solid rgba(55, 65, 81, 0.95);
      font-size: 13px;
      color: #e5e7eb;
      display: flex;
      gap: 10px;
      align-items: flex-start;
    }

    .callout-icon {
      width: 18px;
      height: 18px;
      border-radius: 999px;
      background: var(--accent-soft);
      border: 1px solid var(--accent);
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 11px;
      color: var(--accent);
      flex-shrink: 0;
      margin-top: 2px;
    }

    .checklist {
      border-radius: 16px;
      border: 1px dashed rgba(75, 85, 99, 0.9);
      padding: 10px 12px;
      margin-top: 10px;
      background: rgba(15, 23, 42, 0.9);
    }

    .checklist h3 {
      margin-top: 0;
      font-size: 14px;
    }

    .checklist ul {
      margin: 4px 0 0;
      padding-left: 18px;
    }

    .checklist li::marker {
      content: "‚úì ";
      color: var(--success);
      font-weight: 600;
    }

    .faq {
      margin-top: 16px;
      border-top: 1px solid rgba(31, 41, 55, 0.9);
      padding-top: 10px;
    }

    .faq-item + .faq-item {
      margin-top: 8px;
    }

    .faq-q {
      font-size: 14px;
      font-weight: 600;
      margin-bottom: 2px;
    }

    .faq-a {
      font-size: 13px;
      color: var(--muted);
    }

    .sidebar {
      display: flex;
      flex-direction: column;
      gap: 14px;
    }

    .sidebar-card {
      background: radial-gradient(circle at top left, rgba(56, 189, 248, 0.18), transparent 55%),
                  linear-gradient(145deg, #020617, #020617);
      border-radius: var(--radius-xl);
      border: 1px solid rgba(55, 65, 81, 0.95);
      padding: 14px 14px 16px;
    }

    .sidebar-card h3 {
      margin: 0 0 8px;
      font-size: 14px;
    }

    .sidebar-card p {
      margin: 0 0 10px;
      font-size: 13px;
      color: var(--muted);
    }

    .badge {
      display: inline-flex;
      align-items: center;
      gap: 6px;
      padding: 3px 8px;
      border-radius: 999px;
      background: rgba(15, 23, 42, 0.9);
      border: 1px solid rgba(55, 65, 81, 0.9);
      font-size: 11px;
      text-transform: uppercase;
      letter-spacing: 0.16em;
      color: var(--muted);
      margin-bottom: 6px;
    }

    .badge span {
      font-size: 8px;
      color: var(--accent);
    }

    .link-list {
      list-style: none;
      padding: 0;
      margin: 0;
      font-size: 13px;
    }

    .link-list li + li {
      margin-top: 4px;
    }

    .link-list a {
      color: #e5e7eb;
      text-decoration: none;
    }

    .link-list a:hover {
      color: var(--accent);
    }

    .ad-slot {
      margin-top: 8px;
      border-radius: 14px;
      border: 1px dashed rgba(75, 85, 99, 0.9);
      padding: 10px 8px;
      font-size: 11px;
      text-align: center;
      color: var(--muted);
      background: rgba(15, 23, 42, 0.92);
    }

    .ad-slot.small {
      padding: 6px 6px;
      font-size: 10px;
    }

    footer {
      margin-top: 26px;
      padding-top: 16px;
      border-top: 1px solid var(--border-subtle);
      font-size: 11px;
      color: var(--muted);
      display: flex;
      flex-wrap: wrap;
      justify-content: space-between;
      gap: 8px;
    }

    footer a {
      color: var(--muted);
      text-decoration: none;
    }

    footer a:hover {
      color: var(--accent);
    }

    .btn-primary {
      display: inline-flex;
      align-items: center;
      justify-content: center;
      padding: 9px 16px;
      margin-top: 8px;
      border-radius: 999px;
      border: 1px solid rgba(56, 189, 248, 0.9);
      background: radial-gradient(circle at top left, rgba(56, 189, 248, 0.16), transparent 55%);
      color: #e5e7eb;
      font-size: 14px;
      text-decoration: none;
      gap: 6px;
    }

    .btn-primary:hover {
      border-color: #38bdf8;
      color: #f9fafb;
    }
  </style>

</head>

<body>
<div class="page">
  <div class="shell">

    <header>
      <div class="tagline">
        <div class="tagline-pill">
          <span class="tag-dot"></span>
          WHO ¬∑ GLP-1 ¬∑ PROVIDER COMPLIANCE
        </div>
        <span>Skillona.ai ¬∑ Practical compliance micro-guides</span>
      </div>

      <h1>WHO 2026 GLP-1 Compliance Pack ‚Äì Clinics, Telehealth & Pharmacies</h1>

      <p class="subtitle">
        In January 2026, WHO issued a GLP-1 Global Risk Advisory covering semaglutide, tirzepatide, compounded GLP-1
        products and grey-market channels. This page summarises the core changes and shows clinics, tele-health
        platforms, pharmacies, compounders and distributors exactly how to stay compliant ‚Äì with a ready-to-use
        forms & logs pack.
      </p>

      <div class="meta-row">
        <div class="meta-pill">‚è±Ô∏è <strong>Reading time:</strong>&nbsp;10‚Äì15 min</div>
        <div class="meta-pill">üè• <strong>For:</strong>&nbsp;Clinics ¬∑ Tele-health ¬∑ Pharmacies ¬∑ Compounders</div>
        <div class="meta-pill">üåç <strong>Updated:</strong>&nbsp;January 2026 (WHO GLP-1 Advisory)</div>
      </div>
    </header>

    <main>
      <article class="article">
        <div class="article-inner">

          <!-- SECTION 1 -->
          <div class="section-label">Overview</div>
          <h2>1. What actually changed in WHO‚Äôs 2026 GLP-1 advisory</h2>

          <p>The 2026 WHO GLP-1 Global Risk Advisory does <strong>not</strong> ban GLP-1 therapy. It tightens
             how it must be prescribed, documented, transported and marketed worldwide. Core themes:</p>

          <ul>
            <li>global tightening of <strong>eligibility and documentation</strong> for GLP-1 therapy,</li>
            <li>increased scrutiny of <strong>compounded</strong> and cross-border products,</li>
            <li>mandatory justification and consent for <strong>off-label expansion</strong>,</li>
            <li>full <strong>supply-chain verification</strong> ‚Äì including cold-chain integrity,</li>
            <li>restrictions on <strong>weight-loss marketing claims</strong>,</li>
            <li>more structured <strong>adverse event reporting</strong> and audit triggers.</li>
          </ul>

          <p><strong>Who is in scope:</strong> outpatient clinics, tele-health providers, pharmacies,
             compounding facilities, online wellness brands and distributors handling GLP-1 products.</p>

          <div class="callout">
            <div class="callout-icon">!</div>
            <div>
              The advisory is not optional ‚Äúbest practice‚Äù. Payers, regulators and platforms are already
              aligning policies to WHO language ‚Äì <strong>non-compliance becomes an audit magnet</strong>.
            </div>
          </div>

          <!-- SECTION 2 -->
          <div class="section-label">Risk Clusters</div>
          <h2>2. GLP-1 risk categories WHO focuses on in 2026</h2>

          <p>WHO highlights four critical risk clusters that regulators will track:</p>

          <ul>
            <li><strong>Counterfeit products</strong> ‚Äì online retailers, unverified pharmacies, informal import channels.</li>
            <li><strong>Contaminated / wrong-potency batches</strong> ‚Äì especially from non-accredited compounders.</li>
            <li><strong>Misuse & off-label expansion</strong> ‚Äì cosmetic weight-loss without documentation or consent.</li>
            <li><strong>Cold-chain breaks</strong> ‚Äì shipment or storage deviations that are not logged or disclosed.</li>
          </ul>

          <p>Your compliance system must show that you can <strong>identify, document and act</strong> on each of these risks.</p>

          <!-- SECTION 3 -->
          <div class="section-label">Documentation</div>
          <h2>3. Minimum GLP-1 documentation set WHO expects</h2>

          <p>To pass basic scrutiny, a GLP-1 service line now needs traceable documentation for:</p>

          <ul>
            <li>patient eligibility & prescribing rationale,</li>
            <li>off-label justification + informed consent (where applicable),</li>
            <li>full supply-chain and batch traceability,</li>
            <li>cold-chain temperature logs for all refrigerated stock,</li>
            <li>compounding partner licences, COAs and sterility/potency data,</li>
            <li>adverse event reports and escalation decisions,</li>
            <li>marketing & claims review logs.</li>
          </ul>

          <div class="checklist">
            <h3>Core GLP-1 compliance file (per organisation)</h3>
            <ul>
              <li>Eligibility checklist & prescribing forms.</li>
              <li>Off-label informed consent templates.</li>
              <li>Cold-chain log sheets + deviation SOP.</li>
              <li>Supplier & compounding verification forms.</li>
              <li>Adverse event forms and escalation tree.</li>
              <li>Marketing review checklist + sign-offs.</li>
            </ul>
          </div>

          <!-- SECTION 4 -->
          <div class="section-label">Off-Label & Consent</div>
          <h2>4. Off-label GLP-1 use ‚Äì what must be in the file</h2>

          <p>Off-label prescribing remains legal in many countries, but WHO treats it as a major
             <strong>regulatory risk surface</strong>. For each off-label patient, your file should contain:</p>

          <ul>
            <li>diagnosis / indication and why GLP-1 is chosen,</li>
            <li>clear note that use is <strong>outside approved label</strong>,</li>
            <li>alternatives discussed (lifestyle, other pharmacologic options),</li>
            <li>written informed consent, signed and dated,</li>
            <li>titration / monitoring plan and follow-up schedule.</li>
          </ul>

          <div class="callout">
            <div class="callout-icon">i</div>
            <div>
              In recent audits, missing off-label rationale + consent is one of the fastest ways
              regulators categorise a GLP-1 service as ‚Äúnon-compliant high risk‚Äù.
            </div>
          </div>

          <!-- SECTION 5 -->
          <div class="section-label">Supply Chain</div>
          <h2>5. Supply-chain & cold-chain ‚Äì what WHO expects you to prove</h2>

          <p>WHO‚Äôs advisory links many serious events to poor supply-chain control. You must be able to show:</p>

          <ul>
            <li>verified supplier licences and accreditations,</li>
            <li>COAs and independent lab testing for compounded product,</li>
            <li>tamper-evident packaging and lot/batch tracking,</li>
            <li>validated cold-chain storage equipment,</li>
            <li>24/7 temperature logging with deviation alerts,</li>
            <li>quarantine + destruction records for suspect batches.</li>
          </ul>

          <div class="checklist">
            <h3>Cold-chain & supplier quick audit list</h3>
            <ul>
              <li>Each batch linked to a supplier verification form.</li>
              <li>Temperature logs stored and backed up (minimum 5 years).</li>
              <li>Deviation SOP: who is notified, how product is quarantined.</li>
              <li>Compounding partners mapped to USP & local standards.</li>
            </ul>
          </div>

          <!-- SECTION 6 -->
          <div class="section-label">Audits & Red Flags</div>
          <h2>6. Audit triggers under the 2026 GLP-1 framework</h2>

          <p>Regulators and payers are likely to investigate GLP-1 providers when they see:</p>

          <ul>
            <li>very rapid patient growth without matching documentation,</li>
            <li>high volume of compounded GLP-1 from poorly documented sources,</li>
            <li>missing cold-chain logs or inconsistent temperature records,</li>
            <li>marketing promising guaranteed results or ‚Äúno side effects‚Äù,</li>
            <li>off-label expansion with no recorded rationale or consent,</li>
            <li>clusters of adverse events not escalated or reported.</li>
          </ul>

          <p>Your defence is a <strong>single organised compliance pack</strong> that shows you anticipated and controlled these risks.</p>

          <!-- DOWNLOAD SECTION -->
          <div class="section-label">Download Pack</div>
          <h2>7. Download the GLP-1 WHO 2026 Compliance Pack (PDF)</h2>

          <p>
            To avoid building everything from scratch, the
            <strong>GLP-1 WHO 2026 Compliance Pack</strong> includes ready-to-use, copy/paste assets:
          </p>

          <ul>
            <li>GLP-1 eligibility checklist & prescribing rationale template.</li>
            <li>Off-label informed consent form (provider + patient signatures).</li>
            <li>Cold-chain log sheets + deviation procedure summary.</li>
            <li>Supplier & compounding pharmacy verification forms.</li>
            <li>Adverse event reporting form + escalation options.</li>
            <li>Marketing & claims compliance checklist.</li>
            <li>Final one-page GLP-1 compliance checklist for internal audits.</li>
          </ul>

          <a class="btn-primary" href="https://branimirvrnoga.gumroad.com/l/WHOGLP-12026guidance" target="_blank" rel="noopener">
            üëâ Download the GLP-1 WHO 2026 Compliance Pack (PDF)
          </a>

          <!-- FAQ -->
          <div class="section-label">FAQ</div>
          <h2>8. WHO GLP-1 2026 ‚Äì provider FAQ</h2>

          <div class="faq-item">
            <div class="faq-q">Is the WHO GLP-1 advisory legally binding?</div>
            <div class="faq-a">
              WHO does not legislate, but national regulators, payers and professional
              bodies are already aligning policies with the advisory language. In practice,
              <strong>non-alignment quickly becomes a liability and audit risk</strong>.
            </div>
          </div>

          <div class="faq-item">
            <div class="faq-q">Who should own GLP-1 compliance inside a clinic?</div>
            <div class="faq-a">
              Ideally one named <strong>GLP-1 compliance lead</strong> coordinates medical,
              pharmacy, logistics and marketing teams ‚Äì and owns the central documentation pack.
            </div>
          </div>

          <div class="faq-item">
            <div class="faq-q">Can we keep offering compounded GLP-1?</div>
            <div class="faq-a">
              Yes, where legally allowed ‚Äì but only with documented supplier verification,
              COAs, sterility/potency evidence and clear patient communication about risks.
            </div>
          </div>

          <div class="faq-item">
            <div class="faq-q">How long do we need to store GLP-1 documentation?</div>
            <div class="faq-a">
              As a conservative baseline, plan for <strong>at least five years</strong> of
              retention for eligibility, consent, supply-chain and adverse event records, or
              longer if local rules require.
            </div>
          </div>

        </div>
      </article>

      <aside class="sidebar">

        <div class="sidebar-card">
          <div class="badge"><span>‚óè</span> CLINIC IMPLEMENTATION</div>
          <h3>GLP-1 Clinic Roll-Out Checklist</h3>
          <p>
            Use the compliance pack as a plug-and-play framework to bring your GLP-1 service line
            in line with WHO 2026 in a single working session.
          </p>
          <div class="ad-slot small">
            Included in the PDF pack: master checklist, forms bundle, internal audit sheet.
          </div>
        </div>

        <div class="sidebar-card">
          <h3>Included forms & logs</h3>
          <p>Every template is copy/paste-ready (Word / PDF friendly):</p>
          <ul class="link-list">
            <li>Eligibility & off-label consent forms</li>
            <li>Cold-chain & supplier verification logs</li>
            <li>Adverse event + escalation forms</li>
            <li>Marketing compliance review checklist</li>
          </ul>
        </div>

        <div class="sidebar-card">
          <h3>Related compliance micro-guides</h3>
          <ul class="link-list">
            <li><a href="/medical-bill-overcharge-charity-care/">Medical Bill Overcharge & Charity Care ‚Äì Reduce hospital debt</a></li>
            <li><a href="/background-check-dispute/">Background Check Dispute ‚Äì Fix employment & tenant reports</a></li>
            <li><a href="/us-credit-report-error-dispute/">U.S. Credit Report Error Dispute ‚Äì Full deletion guide</a></li>
          </ul>
        </div>

        <div class="sidebar-card">
          <div class="badge"><span>‚óè</span> ADS / AFFILIATE</div>
          <h3>Premium placement ‚Äì GLP-1 B2B</h3>
          <p>
            Reserved for GLP-1 compliant tele-health platforms, compounding partners,
            logistics providers or audit/consulting services.
          </p>
          <div class="ad-slot">Ad placeholder ‚Äì GLP-1 compliance, logistics, or B2B audit services.</div>
        </div>

      </aside>
    </main>

    <div class="ad-slot" style="margin-top:22px;">
      Secondary banner slot ‚Äì GLP-1 regulatory training / legal / insurance partners.
    </div>

    <footer>
      <div>¬© 2026 Skillona.ai ¬∑ Educational only. Not medical, legal or regulatory advice.</div>
      <div>
        <a href="/about.html">About</a> ¬∑
        <a href="/disclaimer.html">Disclaimer</a> ¬∑
        <a href="/contact.html">Contact</a>
      </div>
    </footer>

  </div>
</div>

<!-- SCHEMA -->
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "WHO 2026 GLP-1 Compliance Pack ‚Äì Clinics, Telehealth & Pharmacies",
  "description": "GLP-1 WHO 2026 Global Risk Advisory: practical compliance summary and plug-and-play documentation pack for clinics, telehealth providers, pharmacies, compounders and distributors.",
  "image": "https://skillona.ai/assets/og/glp1-who-guidance-2026.png",
  "author": {
    "@type": "Organization",
    "name": "Skillona.ai"
  },
  "publisher": {
    "@type": "Organization",
    "name": "Skillona.ai",
    "logo": {
      "@type": "ImageObject",
      "url": "https://skillona.ai/logo.png"
    }
  },
  "mainEntityOfPage": "https://skillona.ai/glp1-who-guidance-2026/",
  "datePublished": "2026-01-01",
  "dateModified": "2026-01-01"
}
</script>

</body>
</html>
